Anastrozole and letrozole: An investigation and comparison of quality of life and tolerability

Breast Cancer Research and Treatment

Volumn 125, Issue 3, 2011, Pages 741-749

  Dixon, J Michael ^a   Renshaw, Lorna ^a   Langridge, Carolyn ^b   Young, Oliver E ^a   McHugh, Mary ^a   Williams, Linda ^c   Murray, Juliette ^a   MacAskill, E Jane ^a   McCaig, Fiona ^a   Dixon, Oliver M ^a   Fallowfield, Lesley J ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Anastrozole; Breast cancer; Letrozole; Quality of life; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; HORMONE; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BLOATING; BLURRED VISION; BODY HEIGHT; BODY WEIGHT; BONE METABOLISM; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG PREFERENCE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLATULENCE; FUNCTIONAL ASSESSMENT; HOT FLUSH; HUMAN; INCREASED APPETITE; IRRITABILITY; JOINT STIFFNESS; MAJOR CLINICAL STUDY; NAUSEA; NIGHT SWEAT; PATIENT PREFERENCE; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SIDE EFFECT; SLEEP DISORDER; STOMACH DISEASE; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; WEAKNESS; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CROSS-OVER STUDIES; ENDOCRINE SYSTEM; HUMANS; MIDDLE AGED; NITRILES; QUALITY OF LIFE; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 79151471532     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1091-9     Document Type: Article

References (27)

1. ME Cazzaniga G Mustacchi P Pronzato A De Matteis F Di Costanzo I Floriani on behalf of the NORA Study Group 2007 Adjuvant treatment of early breast cancer: do the St. Gallen recommendations influence clinical practice? Results from the NORA study Ann Oncol 18 1976 1980 1:STN:280:DC%2BD2sjktFaktg%3D%3D 10.1093/annonc/mdm365 17761700 (Pubitemid 350286234)
2. A Eisen M Trudeau W Shelley H Messersmith KI Pritchard 2008 Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systemic review Cancer Treat Rev 34 157 174 1:CAS:528:DC%2BD1cXjtl2jtr8%3D 10.1016/j.ctrv.2007.11.001 18164821
3. B Thürlimann A Keshaviah AS Coates The Breast International Group (BIG) 1-98 Collaborative Group, et al. 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747 2757 10.1056/NEJMoa052258 16382061 (Pubitemid 43016814)
4. JF Forbes J Cuzick A Buzdar A Howell JS Tobias M Baum Arimidex, Tamoxifen Alone or in Combination (ATAC) Trialists' Group 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 45 53 10.1016/S1470-2045(07)70385-6 18083636
5. AS Coates A Keshaviah B Thurlimann, et al. 2007 Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 486 492 1:CAS:528:DC%2BD2sXivF2mt7Y%3D 10.1200/JCO.2006.08.8617 17200148 (Pubitemid 350002953)
6. A Buzdar A Howell J Cuzick the Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, et al. 2006 Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial Lancet Oncol 7 633 643 1:STN:280:DC%2BD28vmsVOmsQ%3D%3D 10.1016/S1470-2045(06)70767-7 16887480 (Pubitemid 44123570)
7. PE Goss JN Ingle S Martino, et al. 2005 Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 J Nat Cancer Inst 97 1262 1271 1:CAS:528:DC%2BD2MXpvFKjsrY%3D 10.1093/jnci/dji250 16145047 (Pubitemid 41535367)
8. J Geisler B Haynes G Anker M Dowsett PE Lonning 2002 Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study J Clin Oncol 20 751 757 1:CAS:528:DC%2BD38XhsVGmt7Y%3D 10.1200/JCO.20.3.751 11821457 (Pubitemid 34111382)
9. JM Dixon L Renshaw O Young, et al. 2008 Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer J Clin Oncol 26 1671 1676 1:CAS:528:DC%2BD1cXltlWhsrk%3D 10.1200/JCO.2007.13.9279 18375896
10. J Geisler H Helle D Ekse, et al. 2008 Letrozole is superior to anastrozole suppressing breast cancer tissue and plasma estrogen levels Clin Cancer Res 14 6330 6335 1:CAS:528:DC%2BD1cXhtF2nurbM 10.1158/1078-0432.CCR-07- 5221 18829517
11. BIG 1-98 Collaborative Group H Mouridsen A Giobbie-Hurder A Goldhirsch, et al. 2009 Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 766 776 1:CAS:528:DC%2BD1MXhtVWls7fM 10.1056/NEJMoa0810818 19692688
12. SE Jones C Seynaeve A Hasenburg, et al. 2009 Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer Cancer Res 69 2 suppl 67s (Abstract 15)
13. L Fallowfield 2008 There's many a slip twixt cup and lip: adherence issues in cancer therapy Nat Clin Pract Oncol 5 118 119 10.1038/ncponc1043 18212767 (Pubitemid 351972080)
14. MJ Brady DF Cella F Mo, et al. 1997 Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument J Clin Oncol 15 974 986 1:STN:280:DyaK2s3htlyntQ%3D%3D 9060536 (Pubitemid 27106280)
15. LJ Fallowfield S Leaity A Howell S Benson D Cella 1999 Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine subscale for the FACT-B Breast Cancer Res Treat 55 189 199 1:STN:280:DyaK1MvgvFKksA%3D%3D 10.1023/A:1006263818115 10481946
16. LJ Fallowfield JM Bliss LS Porter, et al. 2006 Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer J Clin Oncol 24 910 917 1:CAS:528:DC%2BD28Xitl2qtrc%3D 10.1200/JCO.2005.03.3654 16484701 (Pubitemid 46638844)
17. L Fallowfield D Cella J Cuzick, et al. 2004 Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial J Clin Oncol 22 4261 4271 1:CAS:528: DC%2BD2cXhtVKju7bF 10.1200/JCO.2004.08.029 15514369 (Pubitemid 41185147)
18. D Cella L Fallowfield P Barker J Cuzick G Locker A Howell ATAC Trialists Group 2006 Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer Breast Cancer Res Treat 100 273 284 10.1007/s10549-006-9260-6 16944295 (Pubitemid 44707921)
19. S Ohsumi K Shimozuma Y Ohashi Y Nomura T Aihara Y Takatsuka 2009 Health-related quality-of-life and psychological distress of postmenopausal breast cancer patients after surgery during the randomized trial, N-SAS BC 03, comparing further tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1 to 4 years: the final results Cancer Res 69 2 suppl 145s 146s 10.1158/0008-5472.SABCS-1136 (Abstract 1136)
20. TJ Whelan PE Goss JN Ingle, et al. 2005 Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women J Clin Oncol 23 6931 6940 1:CAS:528: DC%2BD2MXhtFCrsbvJ 10.1200/JCO.2005.11.181 16157934
21. L Abetz V Barghout S Thomas R Arbuckle 2005 Letrozole did not worsen quality of life relative to placebo in post-menopausal women with early breast cancer: results from the US subjects of the MA-17 study Breast Cancer Res Treat 94 suppl 1 A100 Abstract 2047
22. HB Muss D Tu JN Ingle, et al. 2008 Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG Intergroup Trial MA.17 J Clin Oncol 26 1956 1964 1:CAS:528:DC%2BD1cXlvFaqsrc%3D 10.1200/JCO.2007.12.6334 18332474
23. H Takei S Ohsumi K Shimozuma, et al. 2006 Health-related quality of life and psychological distress of breast cancer patients after surgery during phase III randomized trial comparing tamoxifen, exemestane, and anastrozole: N-SAS BC 04 Breast Cancer Res Treat 100 suppl 1 S189 Abstract A4054
24. RC Coombes LS Kilburn CF Snowdon Intergroup Exemestane Study, et al. 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 559 570 1:CAS:528:DC%2BD2sXhvVGgsro%3D 10.1016/S0140-6736(07)60200-1 17307102 Erratum in: (2007) Lancet 369:906
25. A Howell J Cuzick M Baum ATAC Trialists' Group, et al. 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60 62 1:STN:280:DC%2BD2M%2FhsVartA%3D%3D 10.1016/S0140-6736(05)74803-0 15639680
26. J Cuzick I Sestak D Cella L Fallowfield ATAC Trialists' Group 2008 Treatment emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial Lancet Oncol 9 1143 1148 1:CAS:528:DC%2BD1cXhsVWrsL7J 10.1016/S1470-2045(08)70259-6 18976959
27. R Thomas S Godward A Makris D Bloomfield AM Moody M Williams 2004 Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole Clin Oncol (R Coll Radiol) 16 485 491 1:STN:280:DC%2BD2critVWitA%3D%3D